الفهرس 
Title : Ivabradine in patients with systemic inflammatory response syndrome
AbstractOnly 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
This was a prospective case control study to be conducted on 40 patients with SIRS to assess the use of Ivabradine in patients who developed SIRS and compare this group with patients who developed SIRS without Ivabradine use.The study population included 40 patients who developed SIRS and admitted to ICU. Eligible patients aged {u2265}18 years and presented with suspected SIRS were evaluated in the ED and admitted to ICU where confirmed the primary diagnosis according to the following criteria (two of the following): temperature: >38C{u00BA} or < 36 C{u00BA}, heart rate > 90 BPM or SBP < 90 mmHg despite fluid resuscitation, respiratory rate > 20, Pco2< 32 mmHg, WBCs > 11 000 OR < 4 000/MM³with immature bands >10% and suspected source of sepsis. Patients were divided into two groups: group I: SIRSpatients with Ivabradine treatment and group II: SIRS patient without Ivabradine treatment. Laboratory and hemodynamic parameters were measured for patients upon enrollment to the emergency department, where initially heart rate, systolic and diastolic arterial pressure, body temperature and respiratory rate were measured Arterial blood gas, CBC, liver function tests, kidney function tests, electrolytes, coagulation function and C-reactive protein (CRP) were taken and recorded Within 24 hours before Ivabradine treatment echocardiography and chest X-ray were carried out in addition to conventional history inquiry, BMI, physical examination, and collection of relevant laboratory and imaging examination data. Echocardiography parameters: LVEDD, LVESD, EF, LAD, CI (cardiac index) on day 0 and on follow up after 2 days. Regarding base line data, we found thatthe mean age of all patients was (49.7 ± 16.4) years.Regarding gender of the patients, the majority (60%) were males; while (40%) were females